98 related articles for article (PubMed ID: 15955741)
1. Rehabilitation of cancer through oncogene inactivation.
Shachaf CM; Felsher DW
Trends Mol Med; 2005 Jul; 11(7):316-21. PubMed ID: 15955741
[TBL] [Abstract][Full Text] [Related]
2. Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy.
Shachaf CM; Felsher DW
Cancer Res; 2005 Jun; 65(11):4471-4. PubMed ID: 15930260
[TBL] [Abstract][Full Text] [Related]
3. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.
Shachaf CM; Kopelman AM; Arvanitis C; Karlsson A; Beer S; Mandl S; Bachmann MH; Borowsky AD; Ruebner B; Cardiff RD; Yang Q; Bishop JM; Contag CH; Felsher DW
Nature; 2004 Oct; 431(7012):1112-7. PubMed ID: 15475948
[TBL] [Abstract][Full Text] [Related]
4. Sustained loss of a neoplastic phenotype by brief inactivation of MYC.
Jain M; Arvanitis C; Chu K; Dewey W; Leonhardt E; Trinh M; Sundberg CD; Bishop JM; Felsher DW
Science; 2002 Jul; 297(5578):102-4. PubMed ID: 12098700
[TBL] [Abstract][Full Text] [Related]
5. Tumor dormancy and oncogene addiction.
Felsher DW
APMIS; 2008; 116(7-8):629-37. PubMed ID: 18834407
[TBL] [Abstract][Full Text] [Related]
6. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation.
Boxer RB; Jang JW; Sintasath L; Chodosh LA
Cancer Cell; 2004 Dec; 6(6):577-86. PubMed ID: 15607962
[TBL] [Abstract][Full Text] [Related]
7. Conditional transgenic models define how MYC initiates and maintains tumorigenesis.
Arvanitis C; Felsher DW
Semin Cancer Biol; 2006 Aug; 16(4):313-7. PubMed ID: 16935001
[TBL] [Abstract][Full Text] [Related]
8. Oncogene addiction: sometimes a temporary slavery.
Jonkers J; Berns A
Cancer Cell; 2004 Dec; 6(6):535-8. PubMed ID: 15607957
[TBL] [Abstract][Full Text] [Related]
9. Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis.
Pelengaris S; Abouna S; Cheung L; Ifandi V; Zervou S; Khan M
BMC Biol; 2004 Dec; 2():26. PubMed ID: 15613240
[TBL] [Abstract][Full Text] [Related]
10. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?
Felsher DW
Cancer Res; 2008 May; 68(9):3081-6; discussion 3086. PubMed ID: 18451131
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic silencing of cell adhesion molecule 1 in different cancer progenitor cells of transgenic c-Myc and c-Raf mouse lung tumors.
Reamon-Buettner SM; Borlak J
Cancer Res; 2008 Sep; 68(18):7587-96. PubMed ID: 18794147
[TBL] [Abstract][Full Text] [Related]
12. Is oncogene addiction angiogenesis-dependent?
Folkman J; Ryeom S
Cold Spring Harb Symp Quant Biol; 2005; 70():389-97. PubMed ID: 16869776
[TBL] [Abstract][Full Text] [Related]
13. Reversibility of oncogene-induced cancer.
Felsher DW
Curr Opin Genet Dev; 2004 Feb; 14(1):37-42. PubMed ID: 15108803
[TBL] [Abstract][Full Text] [Related]
14. Differential alteration of stem and other cell populations in ducts and lobules of TGFalpha and c-Myc transgenic mouse mammary epithelium.
Chepko G; Slack R; Carbott D; Khan S; Steadman L; Dickson RB
Tissue Cell; 2005 Oct; 37(5):393-412. PubMed ID: 16137731
[TBL] [Abstract][Full Text] [Related]
15. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo.
Blyth K; Vaillant F; Hanlon L; Mackay N; Bell M; Jenkins A; Neil JC; Cameron ER
Cancer Res; 2006 Feb; 66(4):2195-201. PubMed ID: 16489021
[TBL] [Abstract][Full Text] [Related]
16. Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer.
Hu XT; Zhang FB; Fan YC; Shu XS; Wong AH; Zhou W; Shi QL; Tang HM; Fu L; Guan XY; Rha SY; Tao Q; He C
Oncogene; 2009 Jul; 28(26):2466-75. PubMed ID: 19448674
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic "bivalently marked" process of cancer stem cell-driven tumorigenesis.
Balch C; Nephew KP; Huang TH; Bapat SA
Bioessays; 2007 Sep; 29(9):842-5. PubMed ID: 17688287
[TBL] [Abstract][Full Text] [Related]
19. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression.
Toyo-oka K; Bowen TJ; Hirotsune S; Li Z; Jain S; Ota S; Escoubet-Lozach L; Garcia-Bassets I; Lozach J; Rosenfeld MG; Glass CK; Eisenman R; Ren B; Hurlin P; Wynshaw-Boris A
Cancer Res; 2006 Jun; 66(11):5565-73. PubMed ID: 16740691
[TBL] [Abstract][Full Text] [Related]
20. Frequent methylation-associated silencing of a candidate tumor-suppressor, CRABP1, in esophageal squamous-cell carcinoma.
Tanaka K; Imoto I; Inoue J; Kozaki K; Tsuda H; Shimada Y; Aiko S; Yoshizumi Y; Iwai T; Kawano T; Inazawa J
Oncogene; 2007 Sep; 26(44):6456-68. PubMed ID: 17438526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
